2023
DOI: 10.1016/j.xagr.2023.100203
|View full text |Cite
|
Sign up to set email alerts
|

Live birth prevalence of hemolytic disease of the fetus and newborn in the United States from 1996 to 2010

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

1
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 20 publications
(3 citation statements)
references
References 28 publications
1
2
0
Order By: Relevance
“…They cite an Rh-related sensitization risk of 1.6 per 1000 pregnancies, although their reference states that “Rh-induced HDFN live birth prevalence rates ranged from 44.4 to 98.7 per 100 000 births,” or less than 1 per 1000. This is consistent with the population sensitization rate following introduction of Rh immunoglobulin administration at 28 weeks’ gestation, but not earlier in pregnancy . Other causes of sensitization not prevented by Rh immunoglobulin explain some of the difference.…”
supporting
confidence: 83%
“…They cite an Rh-related sensitization risk of 1.6 per 1000 pregnancies, although their reference states that “Rh-induced HDFN live birth prevalence rates ranged from 44.4 to 98.7 per 100 000 births,” or less than 1 per 1000. This is consistent with the population sensitization rate following introduction of Rh immunoglobulin administration at 28 weeks’ gestation, but not earlier in pregnancy . Other causes of sensitization not prevented by Rh immunoglobulin explain some of the difference.…”
supporting
confidence: 83%
“…To the Editor Rh immunoglobulin use by Rh-negative pregnant individuals reduces the risk of HDFN—having saved hundreds of thousands of lives and preserved the reproductive capacities of millions of individuals . HDFN, including due to Rh sensitization, still remains a public health issue, with an estimated incidence of 1.6 per 1000 live births . As reported in 1970, the immunization risk among pregnant individuals with prior abortions directly correlated with gestational age, increasing from the first to the third month of gestation and was observed in 2.8% (26/932) of these individuals .…”
mentioning
confidence: 98%
“…This raises concerns about the reliability of gestational age as an indicator for Rh immunoglobulin administration unless ultrasonography is provided for all of these individuals. Unfortunately, HDFN is not uncommon, affecting approximately 1.6 per 1000 pregnancies, and prevention through administration of Rh immunoglobulin remains the most effective treatment option. Any decision to forgo treatment that has demonstrated efficacy in preventing HDFN should be supported by studies with compelling medical outcomes.…”
mentioning
confidence: 99%